{"id":"https://openalex.org/W2012332584","doi":"https://doi.org/10.1158/1535-7163.mct-09-0089","title":"Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib","display_name":"Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib","publication_year":2009,"publication_date":"2009-06-01","ids":{"openalex":"https://openalex.org/W2012332584","doi":"https://doi.org/10.1158/1535-7163.mct-09-0089","mag":"2012332584","pmid":"https://pubmed.ncbi.nlm.nih.gov/19509243","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2862725"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-09-0089","doi":"https://doi.org/10.1158/1535-7163.mct-09-0089","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-0089","pdf_url":"https://aacrjournals.org/mct/article-pdf/8/6/1438/1885203/1438.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/mct/article-pdf/8/6/1438/1885203/1438.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009937027","display_name":"Shining Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shining Wang","raw_affiliation_strings":["Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I84392919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052503472","display_name":"Qingyu Stephanie Zhou","orcid":"https://orcid.org/0000-0002-4389-1582","observed_orcids":["https://orcid.org/0000-0002-4389-1582"]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qingyu Zhou","raw_affiliation_strings":["Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I84392919"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056500955","display_name":"James M. Gallo","orcid":"https://orcid.org/0000-0003-1553-4817","observed_orcids":["https://orcid.org/0000-0003-1553-4817"]},"institutions":[{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James M. Gallo","raw_affiliation_strings":["Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I84392919"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5056500955"],"corresponding_institution_ids":["https://openalex.org/I84392919"],"apc_list":null,"apc_paid":null,"fwci":3.9268,"has_fulltext":true,"cited_by_count":32,"citation_normalized_percentile":{"value":0.93345572,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"8","issue":"6","first_page":"1438","last_page":"1447"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.24240000545978546,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.24240000545978546,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.18209999799728394,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11829","display_name":"Mathematical Biology Tumor Growth","score":0.13670000433921814,"subfield":{"id":"https://openalex.org/subfields/2611","display_name":"Modeling and Simulation"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetic-pharmacodynamic-modeling","display_name":"pharmacokinetic-pharmacodynamic modeling","score":0.9150000214576721},{"id":"https://openalex.org/keywords/egfrviii-mutation","display_name":"EGFRvIII mutation","score":0.7390000224113464},{"id":"https://openalex.org/keywords/erk1-2-phosphorylation","display_name":"ERK1/2 phosphorylation","score":0.7059999704360962},{"id":"https://openalex.org/keywords/tumor-growth-modeling","display_name":"tumor growth modeling","score":0.6460000276565552},{"id":"https://openalex.org/keywords/brain-tumors","display_name":"brain tumors","score":0.5659999847412109},{"id":"https://openalex.org/keywords/blood-brain-barrier-penetration","display_name":"blood-brain barrier penetration","score":0.984000027179718},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.7300000190734863},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.3630000054836273}],"concepts":[{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9235031604766846},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7867487668991089},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7236603498458862},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6817439198493958},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6761637926101685},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5205070376396179},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4772096276283264},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4191140830516815},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40229901671409607},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.3986862599849701},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3344268202781677},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24261388182640076},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.19814828038215637},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D005909","descriptor_name":"Glioblastoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010766","descriptor_name":"Phosphorylation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013810","descriptor_name":"Therapeutic Equivalency","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019950","descriptor_name":"Mitogen-Activated Protein Kinase 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047368","descriptor_name":"Tumor Burden","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D048052","descriptor_name":"Mitogen-Activated Protein Kinase 3","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D066246","descriptor_name":"ErbB Receptors","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-09-0089","doi":"https://doi.org/10.1158/1535-7163.mct-09-0089","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-0089","pdf_url":"https://aacrjournals.org/mct/article-pdf/8/6/1438/1885203/1438.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:19509243","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19509243","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2862725","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2862725","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.mct-09-0089","doi":"https://doi.org/10.1158/1535-7163.mct-09-0089","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-0089","pdf_url":"https://aacrjournals.org/mct/article-pdf/8/6/1438/1885203/1438.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G7349805395","display_name":"Interactions Between Cytotoxic and Antiangiogenic Drugs","funder_award_id":"R01CA072937","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8469942490","display_name":null,"funder_award_id":"CA 072937","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G8999998882","display_name":"Development of Targeted Anticancer Drugs","funder_award_id":"R01CA127963","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G94195704","display_name":null,"funder_award_id":"CA127963","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2012332584.pdf","grobid_xml":"https://content.openalex.org/works/W2012332584.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W648460181","https://openalex.org/W1981078630","https://openalex.org/W2000756020","https://openalex.org/W2010956784","https://openalex.org/W2023489093","https://openalex.org/W2036044314","https://openalex.org/W2037211078","https://openalex.org/W2063851889","https://openalex.org/W2070705072","https://openalex.org/W2091059913","https://openalex.org/W2094796180","https://openalex.org/W2099328184","https://openalex.org/W2125395336","https://openalex.org/W2137551916","https://openalex.org/W2143548516","https://openalex.org/W2144418840","https://openalex.org/W2151126163","https://openalex.org/W2154670277","https://openalex.org/W2165487575","https://openalex.org/W2166476411","https://openalex.org/W2727695111"],"related_works":["https://openalex.org/W2000756020","https://openalex.org/W3134497505","https://openalex.org/W2519978239","https://openalex.org/W2139769169","https://openalex.org/W2286678525","https://openalex.org/W1982083893","https://openalex.org/W3213940250","https://openalex.org/W2265442695","https://openalex.org/W2116780606","https://openalex.org/W1986172193"],"abstract_inverted_index":{"The":[0,107,188,210],"goals":[1],"of":[2,10,24,52,93,181,206,208,212],"this":[3],"investigation":[4],"were":[5,46,85,175],"to":[6,113,134,169,177,186,222],"illustrate":[7,178],"the":[8,71,90,111,129,135,170,193,204,213],"use":[9],"pharmacokinetic":[11],"(PK)/pharmacodynamic":[12],"(PD)":[13],"modeling":[14],"strategies":[15],"in":[16,26,140],"drug":[17,223],"development":[18],"based":[19,117,156],"on":[20,144,157,192],"a":[21,27,99,182,219],"multiple-dose":[22],"study":[23],"gefitinib":[25,48,80,201],"preclinical":[28],"tumor":[29,78,83,105,123,137,158,164,184,200],"model.":[30],"Mice":[31],"bearing":[32],"s.c.":[33],"LN229-wild-type":[34],"epidermal":[35],"growth":[36,119],"factor":[37],"receptor":[38],"or":[39,60],"LN229-EGFRvIII":[40],"mutant":[41],"(a":[42],"sensitizing":[43],"mutation)":[44],"tumors":[45],"administered":[47,133],"at":[49],"oral":[50],"doses":[51],"either":[53],"55":[54],"mg/kg/d":[55,62],"p.o.":[56,63],"x":[57,64],"15":[58,65],"days":[59,146],"30":[61],"days,":[66],"respectively,":[67],"as":[68,87,89],"dictated":[69],"by":[70],"equivalent":[72,215],"PK/PD":[73,214],"dosing":[74,216],"strategy.":[75],"In":[76,160],"each":[77,122],"group,":[79],"plasma":[81],"and":[82,104,148,150,203],"concentrations":[84],"quantitated,":[86],"well":[88],"tumoral":[91],"amounts":[92],"phosphorylated-extracellular":[94],"signal-regulated":[95],"kinase":[96],"1/2":[97],"(pERK),":[98],"selected":[100],"PD":[101,172],"end":[102],"point,":[103],"size.":[106,159],"resultant":[108],"data":[109,167],"provided":[110,190],"basis":[112],"develop":[114],"hybrid":[115],"physiologically":[116],"PK/PD/tumor":[118],"models":[120],"for":[121],"type.":[124],"It":[125],"was":[126],"found":[127],"that":[128],"1.83-fold":[130],"dose":[131],"difference":[132],"two":[136],"groups":[138],"resulted":[139],"analogous":[141],"pERK":[142,171],"profiles":[143],"both":[145],"1":[147],"15,":[149],"further":[151],"induced":[152],"similar":[153],"antitumor":[154],"efficacy":[155],"addition,":[161],"using":[162],"brain":[163,199],"patient":[165],"PK":[166],"linked":[168],"model,":[173],"simulations":[174,189],"conducted":[176],"potential":[179],"applications":[180],"target":[183],"model":[185],"patients.":[187],"insight":[191],"relationships":[194],"between":[195],"blood-brain":[196],"barrier":[197],"penetration,":[198],"concentrations,":[202],"extent":[205],"inhibition":[207],"pERK.":[209],"implementation":[211],"strategy":[217],"offers":[218],"new":[220],"approach":[221],"development.":[224]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}